REGN vs. NVO
Compare and contrast key facts about Regeneron Pharmaceuticals, Inc. (REGN) and Novo Nordisk A/S (NVO).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: REGN or NVO.
Key characteristics
| REGN | NVO | |
|---|---|---|
| YTD Return | 0.56% | 23.25% |
| 1Y Return | 11.47% | 54.12% |
| 3Y Return (Ann) | 21.58% | 52.61% |
| 5Y Return (Ann) | 20.80% | 40.73% |
| 10Y Return (Ann) | 11.44% | 20.57% |
| Sharpe Ratio | 0.66 | 1.71 |
| Daily Std Dev | 20.48% | 32.20% |
| Max Drawdown | -91.81% | -71.28% |
| Current Drawdown | -11.09% | -6.19% |
Fundamentals
| REGN | NVO | |
|---|---|---|
| Market Cap | $98.44B | $551.28B |
| EPS | $34.80 | $2.66 |
| PE Ratio | 25.77 | 46.13 |
| PEG Ratio | 1.46 | 2.40 |
| Revenue (TTM) | $13.12B | $232.26B |
| Gross Profit (TTM) | $7.02B | $148.51B |
| EBITDA (TTM) | $4.65B | $109.81B |
Correlation
The correlation between REGN and NVO is 0.19, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
REGN vs. NVO - Performance Comparison
In the year-to-date period, REGN achieves a 0.56% return, which is significantly lower than NVO's 23.25% return. Over the past 10 years, REGN has underperformed NVO with an annualized return of 11.44%, while NVO has yielded a comparatively higher 20.57% annualized return. The chart below displays the growth of a $10,000 investment in both assets, with all prices adjusted for splits and dividends.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
REGN vs. NVO - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Regeneron Pharmaceuticals, Inc. (REGN) and Novo Nordisk A/S (NVO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
REGN vs. NVO - Dividend Comparison
REGN has not paid dividends to shareholders, while NVO's dividend yield for the trailing twelve months is around 0.65%.
| TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
REGN Regeneron Pharmaceuticals, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
NVO Novo Nordisk A/S | 0.65% | 0.36% | 0.42% | 0.47% | 0.67% | 0.76% | 0.98% | 0.76% | 1.44% | 0.46% | 0.72% | 0.12% |
Drawdowns
REGN vs. NVO - Drawdown Comparison
The maximum REGN drawdown since its inception was -91.81%, which is greater than NVO's maximum drawdown of -71.28%. Use the drawdown chart below to compare losses from any high point for REGN and NVO. For additional features, visit the drawdowns tool.
Volatility
REGN vs. NVO - Volatility Comparison
The current volatility for Regeneron Pharmaceuticals, Inc. (REGN) is 4.04%, while Novo Nordisk A/S (NVO) has a volatility of 6.07%. This indicates that REGN experiences smaller price fluctuations and is considered to be less risky than NVO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
REGN vs. NVO - Financials Comparison
This section allows you to compare key financial metrics between Regeneron Pharmaceuticals, Inc. and Novo Nordisk A/S. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities